Enteropathy-associated T-cell lymphoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | ==Overview== | ||
Common complications of enteropathy-associated T-cell lymphoma include [[ulcer]], [[obstruction]], and [[perforation]] of small intestine.<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref> | Enteropathy-associated T-cell lymphoma is usually a fast-growing (aggressive) lymphoma. Common complications of enteropathy-associated T-cell lymphoma include [[ulcer]], [[obstruction]], and [[perforation]] of small intestine.<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref>Prognosis is generally poor. | ||
==Natural History<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref>== | ==Natural History<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref>== | ||
* Enteropathy-associated T-cell lymphoma is usually a fast-growing (aggressive) lymphoma. | |||
* Enteropathy-associated T-cell lymphoma is associated with celiac disease (sprue). | * Enteropathy-associated T-cell lymphoma is associated with celiac disease (sprue). | ||
* Most adults are diagnosed with [[celiac disease]] at the same time as their lymphoma or shortly before their lymphoma is diagnosed. | * Most adults are diagnosed with [[celiac disease]] at the same time as their lymphoma or shortly before their lymphoma is diagnosed. | ||
* Enteropathy-associated T-cell lymphoma may spread to the liver, spleen, lymph nodes, gallbladder, stomach, colon or skin. | * Enteropathy-associated T-cell lymphoma may spread to the liver, spleen, lymph nodes, gallbladder, stomach, colon or skin. | ||
| Line 16: | Line 15: | ||
:* [[Perforation]] of small intestine | :* [[Perforation]] of small intestine | ||
==Prognosis== | ==Prognosis== | ||
* | * The prognosis for people with enteropathy-associated T-cell lymphoma is often not very good.<ref name= canadiancancer>Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016 </ref> | ||
* Recurrences most frequent in the small intestine<ref name=cancer.gov> Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016</ref> | * Recurrences most frequent in the small intestine.<ref name=cancer.gov> Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016</ref> | ||
* According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months | * According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months. | ||
* The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma | * The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma. | ||
* | * The most influential prognostic factor is bulky nature of disease, defined by a tumor mass greater than 5 cm. <ref name=pmid21566094>{{cite journal |vauthors=Delabie J, etal |title=Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project|journal=Blood |volume=118|issue=148|pages= 148|date=July 2011 |doi=10.1182/blood-2011-02-335216}}</ref> | ||
* [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients | * [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients. | ||
* One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)<ref name="pmid23361910">{{Cite journal | pmid = 23361910| year = 2013| author1 = Jantunen| first1 = E| title = Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT| journal = Blood| volume = 121| issue = 13| pages = 2529-32| last2 = Boumendil| first2 = A| last3 = Finel| first3 = H| last4 = Luan| first4 = J. J.| last5 = Johnson| first5 = P| last6 = Rambaldi| first6 = A| last7 = Haynes| first7 = A| last8 = Duchosal| first8 = M. A.| last9 = Bethge| first9 = W| last10 = Biron| first10 = P| last11 = Carlson| first11 = K| last12 = Craddock| first12 = C| last13 = Rudin| first13 = C| last14 = Finke| first14 = J| last15 = Salles| first15 = G| last16 = Kroschinsky| first16 = F| last17 = Sureda| first17 = A| last18 = Dreger| first18 = P| author19 = Lymphoma Working Party of the EBMT| doi = 10.1182/blood-2012-11-466839}}</ref> | * One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062).<ref name="pmid23361910">{{Cite journal | pmid = 23361910| year = 2013| author1 = Jantunen| first1 = E| title = Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT| journal = Blood| volume = 121| issue = 13| pages = 2529-32| last2 = Boumendil| first2 = A| last3 = Finel| first3 = H| last4 = Luan| first4 = J. J.| last5 = Johnson| first5 = P| last6 = Rambaldi| first6 = A| last7 = Haynes| first7 = A| last8 = Duchosal| first8 = M. A.| last9 = Bethge| first9 = W| last10 = Biron| first10 = P| last11 = Carlson| first11 = K| last12 = Craddock| first12 = C| last13 = Rudin| first13 = C| last14 = Finke| first14 = J| last15 = Salles| first15 = G| last16 = Kroschinsky| first16 = F| last17 = Sureda| first17 = A| last18 = Dreger| first18 = P| author19 = Lymphoma Working Party of the EBMT| doi = 10.1182/blood-2012-11-466839}}</ref> | ||
==References== | ==References== | ||
Revision as of 16:23, 1 February 2016
|
Enteropathy-associated T-cell lymphoma Microchapters |
|
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
FDA on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
CDC on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis in the news |
|
Blogs on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Enteropathy-associated T-cell lymphoma is usually a fast-growing (aggressive) lymphoma. Common complications of enteropathy-associated T-cell lymphoma include ulcer, obstruction, and perforation of small intestine.[1]Prognosis is generally poor.
Natural History[1]
- Enteropathy-associated T-cell lymphoma is usually a fast-growing (aggressive) lymphoma.
- Enteropathy-associated T-cell lymphoma is associated with celiac disease (sprue).
- Most adults are diagnosed with celiac disease at the same time as their lymphoma or shortly before their lymphoma is diagnosed.
- Enteropathy-associated T-cell lymphoma may spread to the liver, spleen, lymph nodes, gallbladder, stomach, colon or skin.
Complications
- Common complications of enteropathy-associated T-cell lymphoma include:[1]
- Ulcer in small intestine
- Obstruction of small intestine
- Perforation of small intestine
Prognosis
- The prognosis for people with enteropathy-associated T-cell lymphoma is often not very good.[1]
- Recurrences most frequent in the small intestine.[2]
- According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months.
- The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma.
- The most influential prognostic factor is bulky nature of disease, defined by a tumor mass greater than 5 cm. [3]
- Autologous stem cell transplantation is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients.
- One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062).[4]
References
- ↑ 1.0 1.1 1.2 1.3 Enteropathy-associated T-cell lymphoma . Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/enteropathy-associated-t-cell-lymphoma/?region=on Accessed on January 27, 2016
- ↑ Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016
- ↑ Delabie J, et al. (July 2011). "Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project". Blood. 118 (148): 148. doi:10.1182/blood-2011-02-335216.
- ↑ Jantunen, E; Boumendil, A; Finel, H; Luan, J. J.; Johnson, P; Rambaldi, A; Haynes, A; Duchosal, M. A.; Bethge, W; Biron, P; Carlson, K; Craddock, C; Rudin, C; Finke, J; Salles, G; Kroschinsky, F; Sureda, A; Dreger, P; Lymphoma Working Party of the EBMT (2013). "Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT". Blood. 121 (13): 2529–32. doi:10.1182/blood-2012-11-466839. PMID 23361910.